Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.

@article{Suzuki2011TimeCO,
  title={Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.},
  author={Takefumi Suzuki and Gary Remington and Tamara Arenovich and Hiroyuki Uchida and Ofer Agid and Ariel Graff-Guerrero and David C. Mamo},
  journal={The British journal of psychiatry : the journal of mental science},
  year={2011},
  volume={199 4},
  pages={
          275-80
        }
}
BACKGROUND Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia. AIMS To address the early time-line for improvement with antipsychotics in treatment-resistant schizophrenia. METHOD Randomised double-blind trials of antipsychotic medication in adult patients with treatment-resistant schizophrenia were investigated (last search June 2010). A series of metaregression analyses were carried out to examine the effect of time on… 

Figures from this paper

Treatment resistant schizophrenia and response to antipsychotics: A review

Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective

At present, pharmacological combination and augmentation strategies cannot be regarded as a generally recommendable evidence-based treatment method for therapy-refractory schizophrenia.

One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis.

Both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment.

Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.

Patients not even minimally improved by week 2 of antipsychotic treatment are unlikely to respond later and may benefit from a treatment change, and the test specificity was significantly moderated by a trial duration of <6 weeks, higher baseline illness severity, and shorter illness duration.

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia

It was demonstrated that 80 mg/d lurasidone, an effective and tolerable dose for non-TRS patients, was also effective in TRS patients but required longer duration of treatment.

Using early antipsychotic response to predict treatment outcome in patients with first-episode psychosis

This work demonstrates that the appropriate time point at which to assess early response differs between antipsychotic drugs, and strong early response is associated with decreased rates of extrapyramidal side-effects, and can predict long-term treatment outcome at least 2 years after treatment initiation.

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

Algorithm-based antipsychotic treatments for schizophrenia compared well to treatment-as-usual in this study and despite an effort to make each group unique in pharmacologic treatment, it was found that pharmacotherapy in the TAU group eventually became similar to that of the ALGO group.

A Repeated Time-to-Positive Symptoms Improvement among Malaysian Patients with Schizophrenia Spectrum Disorders Treated with Clozapine

The developed model provides essential information on the hazard of positive symptoms improvement after the first clozapine dose administration, including modifiable predictors of high clinical importance.

References

SHOWING 1-10 OF 46 REFERENCES

Early Use of Clozapine for Poorly Responding First-Episode Psychosis

The present findings suggest that clozapine may have an important role in the early treatment of first-episode patients whose psychosis does not remit with other second-generation antipsychotics during the first months of treatment.

Onset and Persistence of Antipsychotic Response in Patients With Schizophrenia

Persistent response (occurring either early or later) is more likely achieved with antipsychotic medication than with placebo, and response patterns may be useful in assessing true drug response.

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

This is the first study to prospectively show that early response/non-response to an antipsychotic (risperidone) is a reliable clinical marker of subsequent clinical outcomes and that a ‘switching’ strategy based on this information may lead to greater clinical improvement than staying on a drug for a longer period in some patients.

A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics.

A meta-analysis of randomized, controlled clinical trials of five atypical antipsychotics confirmed the hypothesis that the time-course of symptom response in acute schizophrenia would be nonlinear, with possible implications with respect to trial design and clinical decision-making.

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.

Several variables, including early age at onset of illness and female gender, were found to be predictors of poor response to treatment and the optimal period for a trial of clozapine appeared to be 12-24 weeks.

Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.

Aripiprazole and perphenazine, at the doses used here, can improve the symptoms of schizophrenia in treatment-resistant patients who have failed to respond to olanzapine or risperidone.

Pharmacoepidemiology of Clozapine in 202 Inpatients with Schizophrenia

Although only 19 percent of the patients exhibited improvement at 6 weeks, the response rate at 12 weeks for this naturalistic study cohort was similar to that in the major, double-blind, six-week, controlled, clinical trial of clozapine.

Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia

Ziprasidone was associated with a greater decrease in median prolactin levels and a lower incidence of clinically significant weight change, and neither agent caused any clinically important changes in QTc interval.